文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

感染性休克早期辅助使用血管加压素启动时机:目标试验模拟研究

Effect of early adjunctive vasopressin initiation for septic shock patients: a target trial emulation.
PubMed 文献 · Crit Care · 2025-05-12
一句话结论目标试验模拟显示,感染性休克患者早期(≤6小时)辅助使用血管加压素与30天ICU死亡率降低相关(RR 0.95)。

该多中心目标试验模拟纳入3105例感染性休克患者,比较入ICU 6小时内早期(≤6小时)辅助使用血管加压素与常规治疗对30天ICU死亡率的影响。参数g-formula模拟显示,早期血管加压素组30天ICU死亡率18.45%(95%CI 16.26–20.63),无血管加压素组19.34%(95%CI 17.0–21.68),相对风险0.95(95%CI 0.93–0.98)。在较低去甲肾上腺素剂量(<0.25 µg·kg⁻¹·min⁻¹)下启动血管加压素的死亡率获益尤其明显,且低于拯救脓毒症运动指南推荐剂量时启动即显著。研究期间血管加压素使用率从2015年35.2%升至2021年45.1%(β=+1.3%/年,95%CI +0.46至+2.16,p=0.011)。

要点

  • 早期(≤6小时)辅助使用血管加压素与30天ICU死亡率降低相关:18.45%(95%CI 16.26–20.63) vs 无血管加压素19.34%(95%CI 17.0–21.68),RR 0.95(95%CI 0.93–0.98)。
  • 在较低去甲肾上腺素等效剂量(<0.25 µg·kg⁻¹·min⁻¹)下启动血管加压素,30天ICU死亡率获益尤其明显,且低于拯救脓毒症运动指南推荐剂量时启动即显著。
  • 研究期间血管加压素使用率从2015年35.2%(95%CI 30.0–40.5)升至2021年45.1%(95%CI 40.7–49.6)(β=+1.3%/年,95%CI +0.46至+2.16,p=0.011)。
  • 启动血管加压素时的去甲肾上腺素等效剂量逐年下降(β=-0.05 µg·kg⁻¹·min⁻¹/年,95%CI -0.09至-0.002,p=0.038),总SOFA评分逐年下降(β=-0.1分/年,95%CI -0.18至-0.07,p<0.001)。

适用人群与场景

  • 纳入标准:感染性休克在入ICU 6小时内诊断的患者。
  • 研究场景:多中心ICU。

处置流程与药物剂量

  • 早期组:在入ICU 6小时内启动辅助血管加压素(≤6小时)治疗;对照组:常规治疗(未使用血管加压素)。

研究设计与关键结果

  • 研究设计:多中心目标试验模拟,共纳入3105例符合入选标准的感染性休克患者。
  • 人群特征:平均年龄62岁,平均APACHE III评分83分;在血管加压素治疗前6小时内,1864例(60%)接受有创机械通气。
  • 主要终点(30天ICU死亡率):早期血管加压素组18.45%(95%CI 16.26–20.63) vs 无血管加压素组19.34%(95%CI 17.0–21.68),相对风险0.95(95%CI 0.93–0.98)。
  • 亚组分析:在较低去甲肾上腺素等效剂量(<0.25 µg·kg⁻¹·min⁻¹)下启动血管加压素时,30天ICU死亡率获益尤其明显,且低于拯救脓毒症运动指南推荐剂量时启动即显著。
  • 次要结局:延迟启动血管加压素对30天ICU死亡率的影响、启动血管加压素时去甲肾上腺素等效剂量对30天ICU死亡率的影响(见下文趋势分析)。
  • 时间趋势:血管加压素使用率从2015年35.2%(95%CI 30.0–40.5)升至2021年45.1%(95%CI 40.7–49.6)(β=+1.3%/年,95%CI +0.46至+2.16,p=0.011)。
  • 启动血管加压素时的去甲肾上腺素等效剂量逐年下降(β=-0.05 µg·kg⁻¹·min⁻¹/年,95%CI -0.09至-0.002,p=0.038),总SOFA评分逐年下降(β=-0.1分/年,95%CI -0.18至-0.07,p<0.001)。

证据类型、等级与局限

  • 证据类型:多中心目标试验模拟(参数g-formula模拟)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,感染性休克患者从早期血管加压素给药中获益,这些发现有助于设计早期辅助使用血管加压素的前瞻性随机对照试验。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In septic shock, the optimal timing of adjunctive vasopressin initiation shock is unknown. We aimed to assess the effect of its early initiation for patients with septic shock.

METHODS: We conducted a multicenter target trial emulation to estimate the intensive care unit (ICU) mortality effect of early (≤ 6 h) adjunctive vasopressin compared with usual care. Eligible patients had septic shock diagnosed within 6 h of ICU admission. The primary outcome of this study was 30-day ICU mortality. Subgroup analyses were conducted to test the interaction of early vasopressin start with peak norepinephrine-equivalent dose (NED) at 6 h, APACHE score, peak lactate at 6 h and invasive mechanical ventilation. Secondary outcomes were the impact of delayed vasopressin introduction on 30-day ICU mortality and effect of NED at vasopressin start on 30-day ICU mortality. We used the parametric g-formula to emulate a target trial.

RESULTS: Overall, 3,105 patients fulfilled the inclusion criteria. Mean age was 62 years and mean APACHE III score was 83. In the first six hours of vasopressor therapy, 1,864 (60%) patients were invasively ventilated. Estimated 30-day ICU mortality was 19.34% (95%CI, 17.0 to 21.68) in the no vasopressin group and 18.45% (95%CI, 16.26 to 20.63) in the early vasopressin group; relative risk 0.95 (95%CI, 0.93 to 0.98). The estimated 30-day ICU mortality effect of starting vasopressin was particularly strong at lower norepinephrine doses (< 0.25 µg.kg-1.min-1) and significant at lower norepinephrine doses than recommended by the Surviving Sepsis Campaign Guidelines. Vasopressin administration progressively increased over the study period, from 35.2% (95%CI, 30.0 to 40.5) in 2015 to 45.1% (95%CI, 40.7 to 49.6) in 2021 (ß = + 1.3% per year; 95%CI, + 0.46 to + 2.16, p = 0.011). Patients had progressively lower norepinephrine equivalent dose (ß = - 0.05 µg.kg-1.min-1 per year; 95%CI, - 0.09 to - 0.002, p = 0.038) and lower total SOFA score (ß = - 0.1 point per year; 95%CI, - 0.18 to - 0.07, p < 0.001) at vasopressin start.

CONCLUSIONS: In this emulation of a hypothetical target trial, patients with septic shock benefited from early vasopressin administration. These findings can help design prospective randomised-control trials of early adjunctive vasopressin use in septic shock.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. White KC, Costa-Pinto R, Blank S, et al. Effect of early adjunctive vasopressin initiation for septic shock patients: a target trial emulation. Crit Care. 2025. PMID: 40355911. doi:10.1186/s13054-025-05401-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。